Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2266 to 2280 of 7682 results

  1. Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]

    In development [GID-TA11263] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Artificial intelligence (AI) technologies for assessing and triaging skin lesions within the urgent suspected skin cancer pathway

    In development [GID-HTE10047] Expected publication date: 19 December 2024

    Health technology evaluations
    In development

  3. Nemolizumab for treating prurigo nodularis [ID6451]

    In development [GID-TA11566] Expected publication date: 21 May 2025

    Technology appraisal guidance
    In development

  4. Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency ID6415

    In development [GID-TA11503] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Seladelpar for previously treated primary biliary cholangitis ID6429

    In development [GID-TA11540] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (MA review of TA823) [ID6324]

    In development [GID-TA11616] Expected publication date: 23 July 2025

    Technology appraisal guidance
    In development

  7. Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]

    Awaiting development [GID-TA11019] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Intrapartum Care - maternal hyponatremia

    In development [GID-NG10431] Expected publication date: TBC

    NICE guideline
    In development

  9. Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]

    In development [GID-TA10994] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor ID 6476

    Awaiting development [GID-TA11584] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123]

    In development [GID-TA11316] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]

    In development [GID-TA11047] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]

    Awaiting development [GID-TA11343] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434]

    In development [GID-TA11570] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development

  15. MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's

    In development [GID-IPG10375] Expected publication date: 12 December 2024

    Interventional procedures guidance
    In development